A $5.9 million Risperdal lawsuit agreement involving Johnson & Johnson and its Janssen unit has been reached in Montana, the reward from which will go towards drug abuse prevention and mental health services in the state, according to its Attorney General’s Office.
The January settlement was reached after a lawsuit filed in 2008 alleged illegal, unfair and deceptive practices in the companies’ promotion of an anti-psychotic drug used to treat bipolar disorder and schizophrenia in adults and adolescents. According to the case, Janssen Pharmaceuticals Inc. concealed the risk for Risperdal gynecomastia and other side effects to stem from its use, and overstated its benefits. According to Montana officials, company research reflected the drug’s potential to cause weight gain, diabetes and cerebrovascular complications in elderly patients.
As part of the Risperdal lawsuit settlement, a KRTV.com report on March 8th indicates that Janssen has also been ordered to refrain from making misleading claims about Risperdal and other medications, and to be transparent about disclosing its possible association with side effects.
More than 200 cases over this drug are now pending in the Philadelphia Court of Common Pleas after being filed by individuals who allegedly experienced complications stemming from Risperdal.
Some monies obtained from the agreement will fund a Prescription Drug Abuse Prevention Program in the state, and a public education specialist will be hired to raise public awareness for a student education program, the article states.
“The Janssen settlement funds give us the resources we need to address the issue and focus on providing meaningful solutions,” said Montana Attorney General, Tim Fox.
Another $1.5 million will be used to fund services and programs through the Montana Mental Health Trust, the Montana publication states, and $675,000 will bolster consumer education protection and enforcement efforts. A total of $825,275 will aid in the reimbursement of Medicaid costs related to the purchase of Risperdal, which were originally paid by the Montana Department of Public Health and Human Services.
“This settlement is not only significant in terms of the amount of money Montana will receive, but also in that it protects our citizens from being prescribed Risperdal based on the types of false statements Janssen previously made to our healthcare providers,” Fox said.
If you experienced Risperdal gynecomastia, a condition referring to male breast growth, or another complication after taking the antipsychotic, contact our Firm today at .